Background
Phase III, double-blind, placebo-controlled RCT. 1038 patients with first-line mCRPC unselected and HRR-selected, receiving abiraterone + prednisone as backbone. Stratified into HRR-positive (HRRm) and HRR-negative (HRRwt) cohorts. HRRm defined by HRR gene alterations (BRCA1/2, ATM, CDK12, CHEK2, FANCA, HDAC2, or other). Niraparib added to abiraterone.
Interventions and follow up
Arm A: Niraparib 200mg/day orally + abiraterone 1000mg/day + prednisone 5mg twice daily
Arm B: Placebo + abiraterone 1000mg/day + prednisone 5mg twice daily
Primary endpoint: Radiographic PFS (rPFS) in HRRm and overall population
mFollow up: 18.6 mo (primary); 26.8 mo (updated)
Arm B: Placebo + abiraterone 1000mg/day + prednisone 5mg twice daily
Primary endpoint: Radiographic PFS (rPFS) in HRRm and overall population
mFollow up: 18.6 mo (primary); 26.8 mo (updated)
Results
rPFS (BRCA1/2-mutated): 16.6 vs 10.9 mo, HR 0.53, P=.001
rPFS (HRRm all genes): 16.5 vs 13.7 mo, HR 0.73, P=.022
rPFS (HRRwt cohort): Futility declared — no benefit (HR 1.09)
OS (BRCA1/2-mutated): HR 0.88 — not significant at interim
rPFS (HRRm all genes): 16.5 vs 13.7 mo, HR 0.73, P=.022
rPFS (HRRwt cohort): Futility declared — no benefit (HR 1.09)
OS (BRCA1/2-mutated): HR 0.88 — not significant at interim
Adverse events
Overall: Grade ≥3 AEs 67% vs 46% (HRRm cohort); discontinuation due to AEs 17% vs 5%
Hematologic: Anemia grade ≥3 28.6% vs 7.9%; thrombocytopenia grade ≥3 12.8% vs 2.4%
Cardiovascular: Hypertension grade ≥3 16.9% vs 13.7%
GI/constitutional: Nausea (any) 36.7% vs 20.0%; fatigue grade ≥3 9.0% vs 5.2%
Hematologic: Anemia grade ≥3 28.6% vs 7.9%; thrombocytopenia grade ≥3 12.8% vs 2.4%
Cardiovascular: Hypertension grade ≥3 16.9% vs 13.7%
GI/constitutional: Nausea (any) 36.7% vs 20.0%; fatigue grade ≥3 9.0% vs 5.2%
Conclusions
Niraparib + abiraterone significantly improved rPFS in BRCA1/2-mutated first-line mCRPC, with benefit also seen in the broader HRRm subgroup. No benefit was demonstrated in HRR-wildtype patients, and the HRRwt cohort met pre-specified futility criteria — confirming that PARP inhibition in first-line mCRPC is biomarker-dependent.
Key Limitations
Key Limitations: OS data were immature at the primary and updated rPFS analysis; survival benefit remains unconfirmed in this trial. The HRRm benefit is heterogeneous across gene alterations — BRCA1/2 shows the clearest effect, while ATM, CDK12, and other gene alterations show weaker signals. Grade ≥3 anemia rate of 28.6% in the HRRm arm significantly exceeds that in PROpel and TALAPRO-2, partly attributable to the fixed 200mg niraparib dose (versus weight-adapted or 300mg dosing). The HRRwt cohort was correctly stopped, providing key negative data.
Clinical Context
MAGNITUDE, PROpel, and TALAPRO-2 together established PARP inhibitor + ARPI combinations in first-line mCRPC, with consistent evidence that BRCA1/2-mutated patients derive the greatest benefit. FDA approved niraparib + abiraterone for BRCA-mutated first-line mCRPC in 2023. Among the three approved PARP+ARPI combinations, the choice is often guided by toxicity profile, dose availability, and formulary access.
References
References: Chi KN et al, JCO 2023